550,000
Participants
Start Date
July 1, 2021
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
DPP4
Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin
GLP-1 receptor agonist
Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide
Basal Insulin
degludec, detemir, glargine and NPH
SLGT2
Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin
SU
Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
RECRUITING
HealthCore, Inc., Wilmington
RECRUITING
Greater Plains Collaborative, Beachwood
RECRUITING
Baylor Scott & White, Dallas
RECRUITING
Humana, Lexington
RECRUITING
Brigham and Women's Hospital, Boston
Collaborators (1)
Patient-Centered Outcomes Research Institute
OTHER
Baylor College of Medicine
OTHER
Baylor Scott and White Research Institute
UNKNOWN
The Cleveland Clinic
OTHER
HealthCore, Inc.
INDUSTRY
Humana Inc.
INDUSTRY
Massachusetts General Hospital
OTHER
Medical Outcomes Management
UNKNOWN
University of Iowa
OTHER
Allina Health
UNKNOWN
Intermountain Health Care, Inc.
OTHER
Marshfield Clinic
UNKNOWN
Medical College of Wisconsin
OTHER
University of Missouri-Columbia
OTHER
University of Utah
OTHER
Brigham and Women's Hospital
OTHER